Filing identity and period
Important entity mismatch: The supplied filing is Arsanis, Inc.’s Form 10-Q for the quarter ended March 31, 2018, filed May 10, 2018. It does not identify X4 Pharmaceuticals, Inc.; verify that this is the intended filing before relying on the summary.
Arsanis is a clinical-stage biopharmaceutical company developing monoclonal-antibody therapies for serious infections. Its lead candidate, ASN100, was in a Phase 2 trial to prevent Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company reported no product revenue.
Financial results and position
Amounts below are in U.S. dollars; financial-statement figures are unaudited.
| Metric | Q1 2018 | Q1 2017 or comparison |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $8.1 million | $4.4 million |
| General and administrative expense | $2.8 million | $1.4 million |
| Total operating expenses / operating loss | $11.0 million / $(11.0) million | $5.8 million / $(5.8) million |
| Grant and incentive income | $0.4 million | $0.7 million |
| Net loss | $(10.6) million | $(5.4) million |
| Net loss per share, basic and diluted | $(0.74) | $(10.49) |
| Cash used in operating activities | $12.2 million | $3.5 million |
Margins are not meaningful because the company had no product sales. Q1 2018 R&D included $5.2 million of direct ASN100 costs, versus $2.5 million a year earlier; the increase chiefly reflected clinical-trial and manufacturing/process-development work. G&A rose primarily with public-company costs, staffing, legal and accounting fees.
At March 31, 2018, cash and cash equivalents were $64.0 million (cash, cash equivalents and restricted cash totaled $64.4 million), down from $76.8 million in cash and cash equivalents at December 31, 2017. Total assets were $69.2 million; total liabilities were $20.8 million; and stockholders’ equity was $48.4 million. Debt principal was $14.6 million: $4.1 million under the SVB loan and $10.5 million of FFG loans. Balance-sheet loans payable, net of discounts, totaled $12.0 million. The company had an accumulated deficit of $102.9 million.
Changes, outlook and risks
- Net loss nearly doubled year over year as operating expenses increased $5.1 million. Higher R&D spending, mainly ASN100, and higher public-company G&A costs were partly offset by lower interest expense and the absence of the prior-year derivative-liability fair-value gain.
- Operating cash use increased substantially year over year. The company attributed Q1 2018 working-capital use in part to bonus payments, vendor-payment timing, clinical-material prepayments and higher grant/incentive receivables.
- Management expected cash at quarter-end to fund operating costs, capital expenditures and debt service into the second half of 2019, including completion of the ongoing Phase 2 ASN100 trial and initiation of a subsequent pivotal Phase 3 trial, assuming a successful Phase 2 outcome. The going-concern note separately states cash was expected to be sufficient for at least 12 months from issuance. Both estimates rely on assumptions and additional financing will be needed beyond the projected runway.
- The company expected expenses to rise as it advances ASN100 and other programs. It had no approved products, no product-sales revenue and expected operating losses for the foreseeable future. It may need equity or debt financing, grants, or collaborations; financing may be unavailable or dilute shareholders or require concessions over product rights.
- Material development risks include clinical-trial enrollment and outcome, safety and efficacy, regulatory approval, manufacturing capacity and supply, competition, intellectual-property protection, and dependence on third-party CROs and manufacturers. The filing also discloses Adimab royalty and milestone obligations, Gates Foundation licensing rights and a potential share-redemption remedy for specified uncured breaches.
- Contractual commitments totaled $22.1 million, including $4.5 million of manufacturing commitments due within one year, $15.4 million of debt obligations and $2.2 million of operating lease commitments. Certain contingent milestone, royalty and cancellation payments were excluded because their amount or timing was uncertain.
- Disclosure controls and procedures were assessed as effective at March 31, 2018; management reported no material quarterly change in internal control over financial reporting. The company reported no off-balance-sheet arrangements.
Key facts for investors to verify
- Confirm the issuer identity: the source is Arsanis, Inc., not X4 Pharmaceuticals, Inc.
- Check subsequent ASN100 Phase 2 results, trial progress and any Phase 3 plans; the stated Phase 3 initiation was conditional on a successful Phase 2 outcome.
- Assess cash burn against the stated runway, debt service, manufacturing commitments and the need for additional capital.
- Review the terms and status of SVB and FFG debt, including maturities, interest rates and any potential FFG loan forgiveness provisions.
- Evaluate grant/incentive receivables and dependence on Austrian government funding, FFG and Gates Foundation arrangements.
- Interpret the sharp change in loss per share cautiously: weighted-average shares were 14.3 million in Q1 2018 versus 513,900 in Q1 2017, reflecting the company’s capital structure and IPO history.